Howard Barron
Cardiovascular Disease · Hollywood, FLNPI 1275614992
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,618 and has fallen 97.0% since, to $49 in 2025.
Across 171 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$611
- Abbott$472
- Sanofi-aventis U.S. LLC$311
- Johnson & Johnson$245
- Bayer$241
- Novo Nordisk$197
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,44699%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 36 | $611 |
| Abbott | 15 | $472 |
| Sanofi-aventis U.S. LLC | 6 | $311 |
| Johnson & Johnson | 13 | $245 |
| Bayer | 8 | $241 |
| Novo Nordisk | 11 | $197 |
| Merck | 12 | $194 |
| Boehringer Ingelheim | 10 | $186 |
| Amgen(2 entities) | 10 | $163 |
| Kowa Pharmaceuticals America, Inc. | 8 | $130 |
| Pfizer | 7 | $119 |
| Novartis | 7 | $106 |
| AstraZeneca | 6 | $102 |
| Astellas Pharma US Inc | 6 | $101 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| GE HealthCare | 1 | $26 |
| Angiodynamics, Inc. | 1 | $24 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| GSK | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$252
- Kerendia$119
- Vascepa$115
- Confirm Rx$112
How this compares
$3,463 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hollywood
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.